Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 7/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | PCNA | P12004 | 1/20 | 0.35 |
| ▸ | LIG1 | P18858 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4358439 | 1.00 | GRB2 (0.40) | GRB2DPP4SLC1A1PTPN1DPP7 | |
| SCHEMBL8268878 | 0.88 | PCNA (0.41) | DPP4SLC1A1DPP7ANPEPEPHX1 | |
| SCHEMBL5058348 | 0.88 | PCNA (0.41) | DPP4SLC1A1DPP7ANPEPEPHX1 | |
| Trifluoroacetic Acid SCHEMBL4544157 | 0.77 | SLC6A4 (0.58) | GRB2DPP4PTPN1DPP7ANPEP | |
| SCHEMBL4358436 | 0.76 | DPP4 (0.37) | DPP4SLC1A1DPP7EPHX1 | |
| SCHEMBL8271157 | 0.74 | EPHX1 (0.48) | SLC1A1ANPEPEPHX1 | |
| Trifluoroacetic Acid SCHEMBL588954 | 0.73 | DPP4 (0.45) | GRB2DPP4SLC1A1PTPN1ANPEP | |
| SCHEMBL188321 | 0.73 | SLC7A5 (0.57) | GRB2SLC1A1 | |
| SCHEMBL2129884 | 0.73 | SLC7A5 (0.57) | GRB2SLC1A1 | |
| SCHEMBL188320 | 0.73 | SLC7A5 (0.57) | GRB2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225372-A1 | Amides as Bace Inhibitors | BACE2, BACE1, APP | GRB2 906/4885DPP4 172/4885SLC1A1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.